论文部分内容阅读
目的:比较4种抗绝经后妇女原发性高脂血症方案的临床疗效和安全性,用药物经济学方法进行成本-效果分析。方法:采用随机对照临床研究方法,将符合标准的患者随机分成A组(阿托伐他汀钙片)、B组(瑞舒伐他汀钙片)、C组(非诺贝特缓释胶囊)和D组(非诺贝特缓释胶囊联合辛伐他汀分散片)。疗程均为2个月。治疗前后分别测定各组患者总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)等指标,进行成本-效果分析及安全性评价。结果:A、B、C、D组患者2个月的治疗成本分别为265.8元、246.6元、235.2元和364.5元。在TC、TG和HDL-C等指标上C组成本-效果比最小。在LDL-C指标上B组方案最优。结论:当绝经后妇女原发性高脂血症患者的体检结果以LDL-C过高为主,可优先选择B组方案,如主要问题为TC、TG和HDL-C超标时,可优先选择C组方案。
OBJECTIVE: To compare the clinical efficacy and safety of four anti-postmenopausal women with primary hyperlipidemia and analyze the cost-effectiveness with the method of pharmacoeconomics. Methods: A randomized controlled clinical trial was conducted. Patients who met the criteria were randomly divided into group A (atorvastatin calcium tablets), group B (rosuvastatin calcium tablets), group C (fenofibrate sustained release capsules) and Group D (fenofibrate sustained-release capsules combined with simvastatin dispersible tablets). Treatment are 2 months. The levels of total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) were measured before and after treatment and the cost- Safety evaluation. Results: The treatment costs of 2 months for patients in groups A, B, C and D were 265.8 yuan, 246.6 yuan, 235.2 yuan and 364.5 yuan respectively. In TC, TG and HDL-C and other indicators of C group cost - the effect of the smallest. Group B is optimal on the LDL-C index. CONCLUSIONS: When the test results of primary hyperlipidemia patients in postmenopausal women are predominantly LDL-C, patients in group B may be preferred. If the main problems are excessive levels of TC, TG and HDL-C, they may be given priority Group C program.